Michael Frank
Gastroenterology · New York, NYNPI 1982764510
Payments from drug & device makers
Across 262 payments — averaging $13.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- AbbVie$1K
- Idorsia Pharmaceuticals US Inc$144
- GSK$133
- Lilly USA, LLC$86
- Johnson & Johnson$74
- plus $196 from 6 others
What the payments were for
- Food & beverage$3,459100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 139 | $1,496 |
| AbbVie(2 entities) | 82 | $1,337 |
| Idorsia Pharmaceuticals US Inc | 16 | $144 |
| GSK | 7 | $133 |
| Lilly USA, LLC | 4 | $86 |
| Johnson & Johnson | 4 | $74 |
| Ironwood Pharmaceuticals, Inc | 3 | $63 |
| Novo Nordisk | 2 | $62 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Exact Sciences | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,467 in reported general payments places this provider in the 55th percentile of 1,682 gastroenterology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 32 | $36,266 |
| EliquisApixaban | 17 | $20,609 |
| JanuviaSitagliptin Phosphate | 12 | $19,356 |
| LinzessLinaclotide | 13 | $11,857 |
| Dexlansoprazole DrDexlansoprazole | 23 | $10,017 |
| MyrbetriqMirabegron | 12 | $5,547 |
| DexilantDexlansoprazole | 11 | $3,935 |
| Atorvastatin Calcium | 183 | $2,815 |
| Famotidine | 71 | $1,843 |
| Nebivolol Hcl | 15 | $1,774 |
| SynthroidLevothyroxine Sodium | 17 | $1,657 |
| Telmisartan | 24 | $1,408 |
| Losartan Potassium | 77 | $1,327 |
| Rosuvastatin Calcium | 85 | $1,318 |
| Amlodipine Besylate | 86 | $1,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $86 | $36,26632 claims |
| AbbVieLinzess, Synthroid | $1,337 | $13,51430 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $13 | $3,93511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in New York
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
- David Carr LockeNew York$2.1M
- Arthur KornbluthNew York$1.9M
- Ira JacobsonNew York$1.8M
- James MarionNew York$1.7M
- Jean Frederick ColombelNew York$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.